spacer
The Healthcare Sales & Marketing Network celebrates 24 years serving the medical sales & marketing community.Connecting Medical Independent Sales Reps and Distributors with Manufacturers and New Product LinesConnecting Medical Independent Sales Reps and Distributors with Manufacturers and New Product Lines

Searching News Database:  respiratory distress syndrome 

 HSMN NewsFeed - 5 Nov 2021
SeaStar Medical Presents Data from SCD 005 Clinical Study at the American Society of Nephrology (ASN) Kidney Week 2021 Annual Meeting
Devices
 HSMN NewsFeed - 13 Aug 2021
Rigel Pharmaceuticals Provides Update on COVID-19 Program
Biopharmaceuticals
 HSMN NewsFeed - 1 Jul 2021
Windtree Appoints Diane Carman, Esq. as Senior Vice President and General Counsel
Biopharmaceuticals Personnel
 HSMN NewsFeed - 24 May 2021
Stemedica Signs License Agreement with Pulthera, LLC for all Respiratory Indications including those related to COVID-19
Regenerative Medicine Licensing
 HSMN NewsFeed - 22 Apr 2021
Getinge receives US FDA 510(k) clearance for three products, expanding the Servo ventilator platform
Devices FDA
 HSMN NewsFeed - 10 Feb 2021
Therapeutic Solutions International Acquires Stem Cell Therapy That Successfully Completed FDA Double Blind Placebo Controlled Efficacy Study for Lung Disease
Regenerative Medicine Acquisitions
 HSMN NewsFeed - 7 Oct 2020
Citius Pharmaceuticals Signs an Exclusive Worldwide Licensing Agreement with Novellus Therapeutics for Unique iMSC-Therapy for Acute Inflammatory Respiratory Conditions including COVID-19 Related Acute Respiratory Distress Syndrome (ARDS)
Biopharmaceuticals Regenerative Medicine Licensing
 HSMN NewsFeed - 6 Aug 2020
FDA grants inhaled use IND for RLF-100 (aviptadil) to treat patients with moderate and severe COVID-19 aiming to prevent progression to respiratory failure
Biopharmaceuticals Drug Delivery FDA
 HSMN NewsFeed - 20 Jul 2020
FDA Clears Abivertinib for Phase 2 Safety and Efficacy Study in Hospitalized Patients with Moderate To Severe Covid-19
Biopharmaceuticals FDA
 HSMN NewsFeed - 26 Jun 2020
Citius Receives FDA Response on Pre-Investigational New Drug (PIND) Application for its Induced Mesenchymal Stem Cells (iMSCs) to Treat Acute Respiratory Distress Syndrome (ARDS) in Patients with COVID-19
Biopharmaceuticals FDA
 HSMN NewsFeed - 24 Jun 2020
CytoSorbents Announces Commercial Launch and Immediate Availability of CytoSorb To Treat Cytokine Storm In Many Latin American Countries As COVID-19 Cases Rise
Devices Product Launch
 HSMN NewsFeed - 9 Jun 2020
BioMedInnovations LLC Announces U.S. Food and Drug Administration Has Granted Emergency Use Authorization to Manufacture and Distribute SuppleVent(TM), a Unique and Value-Added Ventilator Technology
Devices FDA
 HSMN NewsFeed - 13 Apr 2020
U.S. FDA Grants CytoSorb(R) Emergency Use Authorization for Use in Patients with COVID-19 Infection
Devices FDA
 HSMN NewsFeed - 31 Mar 2020
CytoSorb(R) Receives Marketing Approval in Mexico with Commercialization to Commence with Partner Fresenius Medical Care
Devices Regulatory
 HSMN NewsFeed - 26 Mar 2020
FDA Grants VERO Biotech Expanded Access Emergency Use for the Treatment of Patients with COVID-19, with the GENOSYL(R) DS, the First and Only FDA-Approved Tankless System for the Delivery of Inhaled Nitric Oxide
Biopharmaceuticals Drug Delivery FDA
 HSMN NewsFeed - 12 Mar 2020
Mallinckrodt Evaluates the Potential Role for Inhaled Nitric Oxide to Treat COVID-19 Associated Lung Complications, Engages with Scientific, Governmental and Regulatory Agencies
Biopharmaceuticals
 HSMN NewsFeed - 9 Dec 2019
Windtree Therapeutics Completes $26.4 Million Private Placement
Biopharmaceuticals Venture Capital
 HSMN NewsFeed - 6 May 2019
Mallinckrodt Announces Encouraging Interim Analysis Results in Phase 4 Registry of INOmax(R) (Nitric Oxide) Gas for Inhalation for Pulmonary Hypertension in Neonates
Biopharmaceuticals
 HSMN NewsFeed - 10 Apr 2019
Getinge Receives 510(k) Clearance From US FDA for Software Upgrade in Servo-u(R) and Servo-n(R) Ventilator Platform
Devices FDA
 HSMN NewsFeed - 1 Oct 2018
FDA Approves KYPROLIS(R) (carfilzomib) Once-Weekly 70 mg/m2 In Combination With Dexamethasone (Kd70) For Patients With Relapsed Or Refractory Multiple Myeloma
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 27 Feb 2018
Amgen Receives Positive CHMP Opinion For Delivery System Of Neulasta(R) (pegfilgrastim)
Biopharmaceuticals Drug Delivery Regulatory
 HSMN NewsFeed - 1 Dec 2017
FDA approves first biosimilar for the treatment of certain breast and stomach cancers
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 13 Nov 2017
EMD Serono Receives FDA Approval for New GONAL-f(R) RFF Redi-ject(R) Pen
Biopharmaceuticals Drug Delivery FDA
 HSMN NewsFeed - 22 Nov 2016
First Successful Treatment of Dengue Fever and Dengue Shock Syndrome Using CytoSorb(R)
Devices
 HSMN NewsFeed - 4 Jul 2016
European Commission Approves Extended Indication For Amgen's Kyprolis(R) (Carfilzomib) For The Treatment Of Relapsed Multiple Myeloma Patients
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 27 Jan 2016
Boehringer Ingelheim's Gilotrif(R) Demonstrated Superiority to Iressa(R) (Gefitinib) in Reducing the Risk of Disease Progression and Treatment Failure in First-Line Treatment of Patients with EGFR Mutation-Positive Advanced Non-Small Cell Lung Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 18 Nov 2015
Spectrum Pharmaceuticals Divests Rights to ZEVALIN(R) (ibritumomab tiuxetan) in Japan and Select Other Ex-US Countries to Mundipharma
Biopharmaceuticals
 HSMN NewsFeed - 6 May 2015
EMD Serono Initiates Co-Promotion of XALKORI(R) (crizotinib) with Pfizer in the United States
Biopharmaceuticals Oncology Distribution
 HSMN NewsFeed - 16 Dec 2013
EMD Serono's Redesigned Fertility Pen Available for Distribution in US
Biopharmaceuticals Drug Delivery Product Launch
 HSMN NewsFeed - 8 Nov 2013
Discovery Labs Announces U.S. Commercial Launch of SURFAXIN(R) (lucinactant)
Biopharmaceuticals Product Launch
 HSMN NewsFeed - 22 Oct 2013
Amgen Acquires Filgrastim Franchise Rights From Roche In 100 Markets
Biopharmaceuticals Acquisitions
 HSMN NewsFeed - 4 Oct 2013
Discovery Labs Announces FDA Approval of SURFAXIN(R) (lucinactant) Updated Product Specifications
Biopharmaceuticals FDA
 HSMN NewsFeed - 11 Sep 2013
ALung Technologies Raises $15.8 Million in Series B-1 Financing
Devices Venture Capital
 HSMN NewsFeed - 3 Sep 2013
Spectrum Pharmaceuticals Launches Marqibo(R) (vinCRIStine sulfate LIPOSOME injection) and Ships First Commercial Orders
Biopharmaceuticals Oncology Product Launch
 HSMN NewsFeed - 14 Mar 2013
Spectrum Pharmaceuticals Gains Rights to Pivotal-Stage Captisol-Enabled(R) Melphalan
Biopharmaceuticals Licensing
 HSMN NewsFeed - 20 Feb 2013
University of Virginia Medical Center Installs Masimo Noninvasive rainbow(R) Technologies to Improve Patient Assessments and Speed Clinical Decisions
Devices Monitoring
 HSMN NewsFeed - 11 Jan 2013
Spectrum Pharmaceuticals Announces Promotion of Joseph Turgeon to Senior Vice President and Chief Commercial Officer as Company Builds on Recent Commercial Reorganization to Advance Growth and Market Penetration over the Next Five Years
Biopharmaceuticals Personnel
 HSMN NewsFeed - 30 Aug 2012
Teva Announces FDA Grants Approval for Tbo-filgrastim for the Treatment of Chemotherapy-Induced Neutropenia
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 20 Jun 2012
CytoSorbents Appoints Dr. Christian Steiner as VP of Sales and Marketing and Hires Core Sales Force That Marks the Official Launch of CytoSorb(R) in Germany
Devices Personnel
 HSMN NewsFeed - 5 Apr 2012
Spectrum Pharmaceuticals to Acquire Allos Therapeutics: Acquisition Expected to Be Accretive on a Cash Basis in Q4 of 2012
Biopharmaceuticals Mergers & Acquisiitons
 HSMN NewsFeed - 22 Mar 2011
FDA Accepts for Review Spectrum Pharmaceuticals’ ZEVALIN(R) Submission for the Removal of the Bioscan
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 21 Jun 2010
Pfizer Prepares for Voluntary Withdrawal of U.S. New Drug Application and for Discontinuation of Commercial Availability of Mylotarg(R)
Biopharmaceuticals Oncology
 HSMN NewsFeed - 10 May 2010
Takeda to Co-Promote VELCADE(R) (bortezomib) for Injection in Japan
Biopharmaceuticals Oncology
 HSMN NewsFeed - 29 Mar 2010
Oxygen Biotherapeutics Now Marketing New Formulation of Dermacyte(TM) Oxygen Concentrate
Biopharmaceuticals Dermatology
 HSMN NewsFeed - 4 Jan 2010
FDA Approves Addition of Sustained Overall Survival Benefit to Label for VELCADE(R) (Bortezomib) for Injection for Patients with Previously Untreated Multiple Myeloma
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 7 Dec 2009
VELCADE(R) (Bortezomib) for Injection Based Combinations Deliver Two-Year Overall Survival Rates of Up to 88 Percent in Patients with Previously Untreated Multiple Myeloma
Biopharmaceuticals Oncology
 HSMN NewsFeed - 3 Nov 2009
ZEVALIN(R) Receives Positive Reimbursement Ruling Using Average Sales Price (ASP) Methodology
Biopharmaceuticals Oncology Reimbursement
 HSMN NewsFeed - 18 Sep 2009
FDA Grants Priority Review Status to Supplement Containing Long-Term Survival Data for VELCADE(R) (bortezomib) for Injection
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 2 Sep 2009
FDA to Review Supplement Containing Long-Term Survival Data For VELCADE(R) (bortezomib) For Injection
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 14 Aug 2009
Oxygen Biotherapeutics, Inc. to Begin Oxycyte(R) Phase II Clinical Trials in Switzerland
Biopharmaceuticals Neurology
 HSMN NewsFeed - 7 May 2009
Cornerstone Therapeutics Announces $70 Million Strategic Transaction With Chiesi Farmaceutici SpA
Biopharmaceuticals Licensing
 HSMN NewsFeed - 24 Mar 2009
Oxygen Biotherapeutics, Inc. Establishes Warfighter Division
Biopharmaceuticals Personnel
 HSMN NewsFeed - 19 Mar 2009
Oxygen Biotherapeutics, Inc. Receives Letter From FDA Outlining Path Forward to Resume Oxycyte Clinical Trials in TBI in U.S.A.
Devices FDA
 HSMN NewsFeed - 17 Mar 2009
Oxygen Biotherapeutics, Inc. to Launch Product Line of Oxycyte(R) Gels for the Over-the-Counter Market
Devices Biopharmaceuticals
 HSMN NewsFeed - 27 Jan 2009
Oxygen Biotherapeutics, Inc. Submits Request for Designation to FDA for Oxycyte(R)-based Wound Care Product
Devices Wound Care FDA
 HSMN NewsFeed - 9 Jan 2009
MedaSorb Technologies Corporation Announces Management Changes
Devices Personnel
 HSMN NewsFeed - 22 Sep 2008
Oxygen Biotherapeutics, Inc. Announces License Agreement for Its Glucose Biosensor Technology
Devices Monitoring Licensing
 HSMN NewsFeed - 12 Sep 2008
Oxygen Biotherapeutics, Inc. Names Robert F. Diegelmann to Lead New Wound Care Division
Devices Wound Care Personnel
 HSMN NewsFeed - 27 Aug 2008
New England Journal of Medicine Publishes Phase III Results of VELCADE(R) (Bortezomib) for Injection in Previously Untreated Multiple Myeloma Patients
Biopharmaceuticals Oncology
 HSMN NewsFeed - 12 Aug 2008
Oxygen Biotherapeutics Develops Gel Version of Oxycyte(R) for Treating Surface Wounds
Biopharmaceuticals Wound Care
 HSMN NewsFeed - 1 Jul 2008
Synthetic Blood International Changes Name to Oxygen Biotherapeutics, Inc.
Biopharmaceuticals
 HSMN NewsFeed - 31 May 2008
VELCADE(R) (Bortezomib) for Injection Based Treatment Delivers Impressive Complete Response and Survival in Patients With Newly Diagnosed Multiple Myeloma
Biopharmaceuticals Oncology
 HSMN NewsFeed - 22 Apr 2008
Synthetic Blood International, Inc. to Seek Shareholder Approval for Name Change
Biopharmaceuticals
 HSMN NewsFeed - 10 Apr 2008
Millennium Announces VELCADE(R) (Bortezomib) for Injection First-Quarter 2008 U.S. Net Sales
Biopharmaceuticals Oncology
 HSMN NewsFeed - 4 Apr 2008
Synthetic Blood International, Inc. Announces Plans to File Protocol for Phase II-b Oxycyte(R) Clinical Trial
Biopharmaceuticals Neurosurgery
 HSMN NewsFeed - 31 Mar 2008
Synthetic Blood International, Inc. Announces New Leadership Roles to Continue Product Development Strategy
Biopharmaceuticals Personnel
 HSMN NewsFeed - 27 Mar 2008
Discovery Labs Adds Two Executives to Its Management Team
Biopharmaceuticals Personnel
 HSMN NewsFeed - 24 Mar 2008
Synthetic Blood International, Inc. Announces Passing of Interim CEO Robert Larsen
Biopharmaceuticals Personnel
 HSMN NewsFeed - 13 Mar 2008
Publication of Clinical Results Underscores VELCADE(R) (Bortezomib) For Injection Based Therapy As a Standard of Care In Newly Diagnosed Multiple Myeloma Patients
Biopharmaceuticals Oncology
 HSMN NewsFeed - 6 Mar 2008
Office of Naval Research Provides $3.5 Million in New Grants for Clinical Research Involving Synthetic Blood International's Oxycyte(R)
Biopharmaceuticals
 HSMN NewsFeed - 26 Feb 2008
Synthetic Blood Announces Department of Defense Grant for Traumatic Brain Injury Clinical Trial with Oxycyte
Biopharmaceuticals Neurosurgery
 HSMN NewsFeed - 20 Feb 2008
Millennium Expands VELCADE(R) (Bortezomib) For Injection Program In Non-Hodgkin's Lymphoma
Biopharmaceuticals Oncology
 HSMN NewsFeed - 12 Feb 2008
Altor BioScience In-Licenses Tissue Factor Antagonists from Genentech
Biopharmaceuticals Licensing
 HSMN NewsFeed - 8 Feb 2008
Synthetic Blood Announces Medical Advisory Board Meeting Results, New Additions to Board
Biopharmaceuticals Personnel
 HSMN NewsFeed - 30 Jan 2008
FDA Grants Priority Review For Velcade(R) (bortezomib) for Injection In Patients with Newly Diagnosed Multiple Myeloma
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 21 Dec 2007
Millennium Submits sNDA for VELCADE(R) (Bortezomib) for Injection for the Treatment of Front-Line Multiple Myeloma
Biopharmaceuticals FDA Oncology
 HSMN NewsFeed - 18 Dec 2007
Anthera's A-001 Receives Orphan Drug Status for the Prevention of Acute Chest Syndrome in Patients With Sickle Cell Disease
Biopharmaceuticals FDA
 HSMN NewsFeed - 17 Dec 2007
Synthetic Blood Announces Oxycyte Development Strategy
Biopharmaceuticals Neurology
 HSMN NewsFeed - 11 Dec 2007
Synthetic Blood Announces Progress with Oxycyte Program in Traumatic Brain Injury
Biopharmaceuticals Neurosurgery
 HSMN NewsFeed - 10 Dec 2007
VELCADE(R) (Bortezomib) for Injection Based Therapy Produced Significant Complete Remission Rates Pre- and Post-Transplantation in IFM Phase III Front-Line Multiple Myeloma Trial
Biopharmaceuticals Oncology
 HSMN NewsFeed - 9 Dec 2007
Phase III Trial of VELCADE(R) (Bortezomib) for Injection Showed Dramatic Fourfold Increase in Complete Remission Rates When Combined With the Most Commonly Used U.S. Regimen in Front-Line Multiple Myeloma
Biopharmaceuticals Oncology
 HSMN NewsFeed - 9 Dec 2007
Highest Reported Complete Remission Rate of 35 Percent Achieved in a Phase III Front-Line Multiple Myeloma Trial With Velcade(R) (Bortezomib) for Injection Based Therapy
Biopharmaceuticals Oncology
 HSMN NewsFeed - 6 Dec 2007
Anthera Pharmaceuticals Names Christopher P. Lowe Chief Financial Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 28 Nov 2007
Synthetic Blood Announces VCURES Receives $1.3 Million From U.S. Navy for Decompression Sickness Research with Oxycyte
Biopharmaceuticals
 HSMN NewsFeed - 26 Nov 2007
New Data to Support VELCADE(R) (Bortezomib) For Injection Based Therapies as Setting New Standards in The Care of Newly Diagnosed Patients With Multiple Myeloma
Biopharmaceuticals Oncology
 HSMN NewsFeed - 20 Nov 2007
Synthetic Blood Announces Major Restructuring
Biopharmaceuticals Personnel
 HSMN NewsFeed - 16 Oct 2007
MedaSorb Completes Key Step to Begin Clinical Study in Europe for CytoSorb(TM) in the Treatment of Sepsis
Devices
 HSMN NewsFeed - 15 Oct 2007
FDA Expands VELCADE(R) (Bortezomib) for Injection Label for Patients with Multiple Myeloma
Biopharmaceuticals FDA Oncology
 HSMN NewsFeed - 26 Sep 2007
New Analysis Suggests First Cycle Use of Neulasta(R) Reduces Febrile Neutropenia Hospitalizations and Chemotherapy Dose Reductions in Breast Cancer Patients Compared to Current Practice
Biopharmaceuticals Oncology
 HSMN NewsFeed - 20 Sep 2007
European Committee Issues Positive Opinion on Wyeth's TORISEL(TM) for Advanced Renal Cell Carcinoma
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 18 Sep 2007
Phase III Clinical Trial in Newly Diagnosed Multiple Myeloma Stopped Early Due to Highly Significant Efficacy Advantage of VELCADE(R) (Bortezomib) for Injection Based Therapy Across All Endpoints
Biopharmaceuticals Oncology
 HSMN NewsFeed - 15 Aug 2007
Millennium Initiates Clinical Trial to EVOLVE the Treatment of Patients with Newly Diagnosed Multiple Myeloma
Biopharmaceuticals Oncology
 HSMN NewsFeed - 30 Jul 2007
MedaSorb to Pursue 6 Billion Dollar Sepsis Market in Europe
Devices Regulatory
 HSMN NewsFeed - 16 Jul 2007
Millennium Initiates Phase III Trial to Determine the Optimal VELCADE(R) (Bortezomib) for Injection Based Therapy in Newly Diagnosed Multiple Myeloma Patients
Biopharmaceuticals Oncology
 HSMN NewsFeed - 2 Jul 2007
VELCADE(R) (bortezomib) for Injection Based Induction Therapy Delivered High Post-Transplant Complete Remission Rate, a Critical Marker for Increased Overall Survival
Biopharmaceuticals Oncology
 HSMN NewsFeed - 28 Jun 2007
VELCADE(R) (Bortezomib) for Injection Based Therapies Produced Complete Remission Rates as High as 54 Percent in Patients With Previously Treated Multiple Myeloma
Biopharmaceuticals Oncology
 HSMN NewsFeed - 28 Jun 2007
VELCADE(R) (Bortezomib) for Injection Based Therapies Achieved Survival Rates as High as 100 Percent in Newly Diagnosed Multiple Myeloma Patients
Biopharmaceuticals Oncology
 HSMN NewsFeed - 4 Jun 2007
New Data on Market-Leading VELCADE(R) (Bortezomib) for Injection Further Strengthen Role in Previously Treated Multiple Myeloma
Biopharmaceuticals Oncology
 HSMN NewsFeed - 4 Jun 2007
Updated Overall Survival Data From Pivotal Herceptin Adjuvant Studies in HER2-Positive Breast Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 3 Jun 2007
Data Show Improved Response Rate When Zevalin Plus Rituximab Follows Short Course First-Line Treatment in Patients with Follicular Lymphoma
Biopharmaceuticals Oncology
 HSMN NewsFeed - 3 Jun 2007
VELCADE(R) (Bortezomib) for Injection Based Therapy Substantially Improves Event-Free Survival and Complete Response Rate in Newly Diagnosed Multiple Myeloma Patients
Biopharmaceuticals Oncology
 HSMN NewsFeed - 3 Jun 2007
VELCADE(R) (bortezomib) for Injection Based Therapies Produced High Complete Response Rates in Newly Diagnosed Non-Hodgkin's Lymphoma Patients
Biopharmaceuticals Oncology
 HSMN NewsFeed - 15 May 2007
Positive Statistical Analysis from Synthetic Blood's Oxycyte Traumatic Brain Injury Trial Indicates Achievement of Primary Endpoint
Biopharmaceuticals Neurology
 HSMN NewsFeed - 1 May 2007
Rituxan(R) Phase II Data in Patients with Relapsing-Remitting Multiple Sclerosis Presented at the American Academy of Neurology
Biopharmaceuticals Neurology
 HSMN NewsFeed - 17 Apr 2007
Millennium Discovers Biomarkers Potentially Predictive of Response to VELCADE(R) (Bortezomib) for Injection
Biopharmaceuticals Oncology
 HSMN NewsFeed - 13 Apr 2007
First Patient Enrolled in Phase 2 'PLASMA' Trial With A-002 for Patients With Coronary Atherosclerosis
Biopharmaceuticals Cardiology
 HSMN NewsFeed - 20 Mar 2007
Anthera Pharmaceuticals, Inc. Announces Appointment of Dr. James Pennington as Executive Vice President & Chief Medical Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 8 Mar 2007
Anthera Pharmaceuticals, Inc. Announces Formation of Clinical Advisory Board for Respiratory and Acute Care Programs
Biopharmaceuticals Personnel
 HSMN NewsFeed - 28 Feb 2007
Vascular BioSciences Extends Patent Portfolio
Biopharmaceuticals
 HSMN NewsFeed - 7 Feb 2007
Dr. David D. Waters Joins Anthera Pharmaceuticals as Cardiovascular Research Fellow
Biopharmaceuticals Personnel
 HSMN NewsFeed - 22 Jan 2007
Ortho Biotech Seeks FDA Approval for DOXIL(R) in Combination with VELCADE(R) to Treat Relapsed/Refractory Multiple Myeloma
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 9 Jan 2007
Anthera Receives IND Approval from FDA to Begin Phase 2 'IMPACTS' Trial With A-001 for Prevention of Acute Chest Syndrome in Patients with Sickle Cell Disease
Biopharmaceuticals
 HSMN NewsFeed - 4 Jan 2007
Anthera Receives FDA Approval to Begin Phase 2 'PLASMA' Trial With A-002 for Patients With Coronary Atherosclerosis
Biopharmaceuticals Cardiology FDA
 HSMN NewsFeed - 22 Dec 2006
Synthetic Blood Reports Positive Preliminary Results From Traumatic Brain Injury Clinical Trial
Biopharmaceuticals Neurosurgery
 HSMN NewsFeed - 14 Dec 2006
Dr. Bob Tepper, President of R&D, to Leave Millennium
Biopharmaceuticals Personnel
 HSMN NewsFeed - 12 Dec 2006
VELCADE(R) (bortezomib) for Injection Incorporated Into NCCN(R) Clinical Practice Guidelines for Newly Diagnosed Multiple Myeloma
Biopharmaceuticals Oncology
 HSMN NewsFeed - 11 Dec 2006
VELCADE(R) (Bortezomib) for Injection Demonstrates Substantial Activity Across Range of Lymphomas
Biopharmaceuticals Oncology
 HSMN NewsFeed - 11 Dec 2006
Positive Results from Combination Trials Build on VELCADE(R) (Bortezomib) for Injection Proven Single-Agent Strength in Relapsed Multiple Myeloma
Biopharmaceuticals Oncology
 HSMN NewsFeed - 11 Dec 2006
Multiple Myeloma Patients Respond to Retreatment with VELCADE(R) (Bortezomib) for Injection
Biopharmaceuticals Oncology
 HSMN NewsFeed - 10 Dec 2006
VELCADE(R) (Bortezomib) for Injection Combination Shows High Complete and Near Complete Response Rate in Preliminary Data From Phase III Front-Line Multiple Myeloma Trial
Biopharmaceuticals Oncology
 HSMN NewsFeed - 8 Dec 2006
FDA Approves VELCADE(R) (Bortezomib) for Injection for Aggressive Form of Non-Hodgkin's Lymphoma
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 16 Nov 2006
FDA Approves Herceptin(R) for the Adjuvant Treatment of HER2-Positive Node-Positive Breast Cancer
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 4 Oct 2006
Schering AG and Biogen Idec Announce Start of the ZEAL Phase III Clinical Trial With Anti-Cancer Drug Zevalin(R)
Biopharmaceuticals Oncology
 HSMN NewsFeed - 29 Sep 2006
FDA Approves Two New Indications for Rituxan(R) in Patients With Non-Hodgkin's Lymphoma
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 6 Sep 2006
Anthera Licenses Portfolio of Anti-Inflammatory Products From Eli Lilly and Company and Shionogi & Co., Ltd.
Biopharmaceuticals Licensing
 HSMN NewsFeed - 28 Aug 2006
Genentech and Biogen Idec Announce Positive Results From a Phase II Trial of Rituxan in Relapsing-Remitting Multiple Sclerosis
Biopharmaceuticals Neurology
 HSMN NewsFeed - 28 Aug 2006
Patient Treatment Completed in Synthetic Blood Traumatic Brain Injury Trial
Biopharmaceuticals Neurosurgery
 HSMN NewsFeed - 9 Aug 2006
Two Additional Traumatic Brain Injury Patients Treated in Synthetic Blood Trial
Biopharmaceuticals Neurosurgery
 HSMN NewsFeed - 12 Jul 2006
Synthetic Blood Updates Traumatic Brain Injury Trial Enrollment
Biopharmaceuticals
 HSMN NewsFeed - 22 Jun 2006
Analysis of Phase III Study Showed Rituxan(R) Plus Methotrexate Reduced Joint Damage in Rheumatoid Arthritis Patients Who Respond Inadequately to TNF Antagonist Therapies
Biopharmaceuticals
 HSMN NewsFeed - 19 Jun 2006
Synthetic Blood Receives Letter of Intent to Initiate Oxycyte Cardiopulmonary Bypass Surgery Registration Trial in Mexico
Biopharmaceuticals Regulatory
 HSMN NewsFeed - 19 May 2006
Synthetic Blood Reaches First Half of Traumatic Brain Injury Trial
Biopharmaceuticals
 HSMN NewsFeed - 10 May 2006
NephroGenex Licenses Pyridorin(TM) for Diabetic Nephropathy and Acute Renal Failure
Biopharmaceuticals Acquisitions Licensing
 HSMN NewsFeed - 30 Mar 2006
Genentech and Biogen Idec Submit Supplemental Biologics License Application for First-Line Use of Rituxan(R) in Low-Grade or Follicular CD20-Positive B-Cell Non-Hodgkin's Lymphoma
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 16 Mar 2006
Synthetic Blood Enrolls First Patient in Phase II Traumatic Brain Injury Study
Biopharmaceuticals Neurology
 HSMN NewsFeed - 28 Feb 2006
FDA Approves Rituxan(R) - The First Targeted B-Cell Therapy for Treatment of Moderate-to-Severe Rheumatoid Arthritis
Biopharmaceuticals FDA
Return to NewsFeed  

 Additional items found! 37

Members: click here for search results from The HSMN Archive (password required)
Members Archive contains 37 additional stories matching:
respiratory distress syndrome
(Password required)
FindReps - Find Great Medical Independent Sales Reps without recruiter fees.
FindReps - available on the Apple App Store for iPhone and iPad.